News
OTLK
8.34
+1.83%
0.15
Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors
These disclosures are from 13Ds filed with the Securities and Exchange Commission. Marriott Vacations Worldwide revealed a new position in the vacation-property management company. Carrols Restaurant Group and Outlook Therapeutics increased their stakes in 2024. Mueller Industries lowered its stake in the industrial products company.
Barron‘s · 14h ago
Weekly Report: what happened at OTLK last week (0415-0419)?
Weekly Report · 4d ago
OUTLOOK THERAPEUTICS® ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF $5.0 MILLION
Reuters · 04/15 20:15
Press Release: Outlook Therapeutics(R) Announces Closing of Private Placement of $5.0 Million
Outlook Therapeutics, Inc. Announces Closing of Private Placement of $5.0 million. Outlook is working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU. The company has the potential to receive additional gross proceeds of up to $8 million.
Dow Jones · 04/15 20:15
Weekly Report: what happened at OTLK last week (0408-0412)?
Weekly Report · 04/15 12:15
Outlook Therapeutics Files Prospectus Supplement Related To Offer, Sale Of Up To $93.7M Of Common Stock That May Be Sold Under Sales Agreement
Benzinga · 04/12 20:33
OUTLOOK THERAPEUTICS - FILES PROSPECTUS SUPPLEMENT RELATED TO OFFER, SALE OF UP TO $93.7 MLN OF COMMON STOCK THAT MAY BE SOLD UNDER SALES AGREEMENT
Reuters · 04/12 20:30
GREAT POINT PARTNERS, LLC REPORTS 9.99% PASSIVE STAKE IN OUTLOOK THERAPEUTICS AS OF APRIL 1- SEC FILING
Reuters · 04/08 20:13
Weekly Report: what happened at OTLK last week (0401-0405)?
Weekly Report · 04/08 12:21
OUTLOOK THERAPEUTICS INC - ON APRIL 1, RECEIVED WRITTEN NOTICE FROM NASDAQ INFORMING COMPANY THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ LISTING RULE
Reuters · 04/02 20:17
Insiders Buying Outlook Therapeutics And 2 Other Stocks
U.S. Stocks closed mixed on Thursday. There were a few notable insider trades. Insider purchases indicate confidence in the company's prospects or that they view the stock as a bargain. CION Investment Corporation and Outlook Therapeutics made notable insider purchases. Rocket Companies, Inc. Also made a notable purchase.
Benzinga · 04/01 14:46
Weekly Report: what happened at OTLK last week (0325-0329)?
Weekly Report · 04/01 12:17
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval
Outlook Therapeutics' drug ONS-5010 is being developed for the treatment of patients with wet age-related macular degeneration. The positive CHMP opinion could mean possible European Approval. European Commission expected to decide upon approval for this in the next few months. The anti-VEGF market size is projected to reach $13.54 billion by 2030.
Seeking Alpha · 03/31 13:25
Outlook Therapeutics files for $300M mixed securities shelf
Healthcare Outlook Therapeutics files for $300M mixed securities shelf Mar. 28, 2024 5:15 p.m. Outlook TherAPEutics, Inc. Filed a prospectus related to the offer and sale of $300m mixed securities. Stock is up 1.7% in the last day.
Seeking Alpha · 03/28 21:15
Outlook Therapeutics shares rise after "buy" rating from BTIG
Outlook Therapeutics shares rise after "buy" rating from BTIG. OTLK up as much as 17.9% at $10.23 on Wednesday, stock is down 50.5% YTD. Outlook was upgraded to " buy" from a previous investment rating of "neutral" BTIG also set a price target of $50 on the stock.
Seeking Alpha · 03/27 17:04
Outlook Therapeutics Raised to Buy From Neutral by BTIG
Dow Jones · 03/27 11:27
Outlook Therapeutics Price Target Announced at $50.00/Share by BTIG
Dow Jones · 03/27 11:27
BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target
Benzinga · 03/27 11:19
Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target
Julian Harrison from BTIG upgraded Outlook Therapeutics to a Buy, with a price target of $50.00. The company has successfully negotiated a Special Protocol Assessment with the FDA for their drug ONS-5010 for wet age-related macular degeneration.
TipRanks · 03/27 10:45
Outlook Therapeutics Grants Stock Options to Top Executives
TipRanks · 03/26 20:33
More
Webull provides a variety of real-time OTLK stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.